Semelhança entre os mecanismos de formação da anemia por soro anti-plaqueta e por benzoato de estradiol

Benzoato de estradiol aplicado em altas doses a cães tem uma ação essencialmente trombocitopênica e o mecanismo de formação da anemia que se estabelece é semelhante ao observado na anemia da purpura experimental pelo sôro anti-plaqueta. O quadro patológico é, em ambos os casos, resultante desta trombocitopenia aguda.

Ação bacteriolítica dos fosfatos (Fosfatólise bacteriana)

1) As bactérias são lisadas pelos fosfatos, cuja atividade lítica varia com o sal de fosfato, os trivalentes sendo mais ativos. 2) A fosfatólise independente da viabilidade da bactéria. 3) A fosfatólise póde interferir nas suspensões com tampões de fosfatos e na preservação de hemoculturas.

Malignant transformation of a rat fibroma by the treatment with an anti-fibrosing drug: CY-168F (Plastenan)

Fifteen albino (Sprague Dawley) rats with subcutaneous transplanted fibromas was used in the present study. The tumour was formed by typical fibroblasts in a dense collagen matrix and was provenient from a fibroma that appeared spontaneously in an albino rat of the same strain. Ultrastructurally collagen disclosed normal periodicity and the fibroblasts showed irregular notched nuclei with irregular distribution of chromatin, that suggests transitional aspects to fibrosarcoma. The 15 animals, from different passage groups, were divided into: 8 animals submitted to treatment with the drug acexamic acid (CY-168F) - N acetyl-amino-6-hexanoic acid (plastenan) and 7 untreated control animals. Three of the treated animals showed a malignant transformation to fibrosarcoma. transitional histological features from typical fibroma to highly indifferentiated fibrosarcoma could be detected in come animal subjected to repeated biopsies. Ultrastructural study disclosed nuclear alterations and hyperactive ergastoplasm and collagen containing inclusions into the cytoplasm of fibroblasts. In the group of 7 untreated naimals, no malignant transformation could be detected histologically. Two aspects deserve attention: the malignant potential of a typical fibroma and the apparent effect of an antifibrosing drug in inducing malignization of this tumour.

EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment

Antibodies against heart vascular structures and striated muscle cells interstitium (EVI antibodies) persist in Chagas' disease patients who had been cured by specific treatment as demonstrated by negative xenodiagnosis, conventional serology (CS) and complement mediated lysis (CoML). On the other hand, EVI antibodies are either present or absent in treated patients presenting positive CS but negative CoML. Since CoML detects antibodies associated to resistance, EVI antibodies are not likely to participate in the control of T. cruzi infections although they might be induced by cross-reacting antigens of heart cells and the parasite. They are neither necessarily related to antibodies responsible for CS. Absorption with T. cruzi and heart tissue confirms the suggestion that EVI antibodies are induced by a number of antigenic determinants, most from heart structures with a minor participation of T. cruzi antigens.

Anticorpos anti-HBs obtidos em coelhos e sua utilização como reagentes para testes sorológicos no diagnóstico da hepatite B

Pela técnica de cromatografia de afinidade, utilizando-se a resina de Sepharose 4B ligada ao anti-HBs, obteve-se na passagem de plasma de portador assintomático de antígeno HBs, um antígeno parcialmente purificado. Este antígeno foi utilizado para a inoculação em coelhos, num esquema de cinco doses, sendo a primeira dose de 1mg e as quatro subseqüentes de 0,5 mg, com intervalos aproximadamente de quinze dias. Observando-se que os títulos não mais variaram após a quinta inoculação, os animais foram sangrados no 62° dia e os anticorpos anti-HBs obtidos foram padronizados através dos seguintes métodos para detecção de antígeno HBs: a) Hemaglutinação passiva reversa (HAPR) – utilizando-se a gamaglobulina específica obtida de soro imune dos coelhos através de cromatografia de afinidade, alcançando uma concentração ótima de apenas 10µg/ml para a sensibilização de hemácias de carneiro a 5%, fixadas com glutaraldeído. B) Contraimunoeletroforese (CIEF) – utilizando-se o soro imune diluído até 1/20 como reagente para a detecção do antígeno HBs. O soro imune anti-HBs foi também utilizado para a conjugação com uma nova resina de Sepharose 4b tendo uma captação aproximada de 0,5 a 1,0mg antígeno HBs por ml de resina após completa saturação.

Infecção bacteriana em pacientes portadores de Leishmaniase visceral

Uma análise retrospectiva de 63 casos de Leishmaniose visceral (L.V.) revelou a presença, em 33 deles, de infecção bacteriana associada. Infecções do trato respiratório foram observadas em 13 (39,3%) pacientes, comprometimento de pele em 4 (12%), do trato urinário em 4 (12%), do ouvido em 3 (9%), e de orofaringe em 2 (6%). Sete (21%) pacientes apresentaram infecção concomitante em múltiplos sítios. Documentação bacteriológica através de isolamneto do agente etiológico foi obtida em 10, não havendo predominância estatisticamente significante de bactérias Gram positivas ou negativas. Houve 9 casos de óbito nestes 63 pacientes, sendo que em 8 deles a infecção bacteriana fazia parte do quadro clínico final. A análise das taxas de globulinas séricas revelou que infecção esteve presente de modo significativo (p < 0.05) em 15/20 (75%) dos pacientes com níveis de globulina sérica [menor ou igual a] 4,0g%. Não houve diferença significativa (p > 0.05) com relação ao número de neutrófilos entre os grupos com e sem infecção bacteriana. Concluiu-se, portanto, que infecção bacteriana é um achado freqüente em pacientes com L.V. e se constitui num sinal de mau prognóstico da doença.

CL 64, 855, a potent do anti-Trypanosoma cruzi drug, is also mutagenic in the salmonella/microsome assay

The nitroimidazole-tiadiazole derivative CL 64,855 (2-amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole, a potent anti-trypanosomal drug, was assayed in a short-term bacterial mutagenicity test with Salmonella typhimurium strains TA 98, TA 100 and TA 102. Results indicate that CL 64,855 is a potent frameshift mutagen detected by strains TA 98 and TA 102. CL 64,855 was able to revert the indicators strains at concentrations as low as 0.1 µg/plate. Metabolic activation experiments with rat liver microsomal fractions did not increase the mutagenic action of Cl 64,855.

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

BACKGROUND: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic potential on human B cell malignancies. METHODS: GBR 401 was partially defucosylated in order to enhance its cytotoxic function. We analyzed the in vitro depleting effects of GBR 401 against B cell lines and primary malignant B cells from patients in the presence or in absence of purified NK cells isolated from healthy donors. In vivo, the antibody dependent cellular cytotoxicity (ADCC) efficacy of GBR 401 was assessed in a B cell depletion model consisting of SCID mice injected with healthy human donor PBMC, and a malignant B cell depletion model where SCID mice are xenografted with both primary human B-CLL tumors and heterologous human NK cells. Furthermore, the anti-tumor activity of GBR 401 was also evaluated in a xenochimeric mouse model of human Burkitt lymphoma using mice xenografted intravenously with Raji cells. Pharmacological inhibition tests were used to characterize the mechanism of the cell death induced by GBR 401. RESULTS: GBR 401 exerts a potent in vitro and in vivo cytotoxic activity against primary samples from patients representing various B-cell malignancies. GBR 401 elicits a markedly higher level of ADCC on primary malignant B cells when compared to fucosylated similar mAb and to Rituximab, the current anti-CD20 mAb standard immunotherapeutic treatment for B cell malignancies, showing killing at 500 times lower concentrations. Of interest, GBR 401 also exhibits a potent direct killing effect in different malignant B cell lines that involves homotypic aggregation mediated by actin relocalization. CONCLUSION: These results contribute to consolidate clinical interest in developing GBR 401 for treatment of hematopoietic B cell malignancies, particularly for patients refractory to anti-CD20 mAb therapies.

Differential effects of two anti-apo-cytochrome c-specific monoclonal antibodies on the function of apo-cytochrome c-specific murine T cell clones.

A murine monoclonal antibody (SJL 2-4) specific for the antigen apo-cytochrome c was shown to inhibit both antigen-induced proliferation and lymphokine secretion by an apo-cytochrome c-specific BALB/c helper T cell clone. The inhibition was specific because additional apo-cytochrome c-specific T cell clones were not inhibited by the same monoclonal antibody. Time course studies of the inhibition indicated that the initial 8 hr of contact between T cell clones and antigen-presenting cells were critical for activation of the T cell clones. Inhibition of T cell functions by antigen-specific antibodies appeared to correlate with the antibody-antigen binding constant because a second monoclonal antibody (Cyt-1-59), with identical specificity but with a lower affinity constant for apo-cytochrome c, had very little inhibitory effect on the proliferation or lymphokine secretion of apo-cytochrome c-specific T cell clones.